Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

FDA Approves SAMSCA(TM) (tolvaptan), The First And Only Oral Vasopressin Antagonist To Treat Patients With Clinically Significant Hypervolemic
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC) announced that the U.S. Food and Drug Administration (FDA) has approved SAMSCA(TM) (tolvaptan) as the only oral selective vasopressin antagonist for the treatment of patients with clinically significant hypervolemic and euvolemic hyponatremia (serum sodium less than 125 mEq/L, or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction) including patients with heart failure, cirrhosis, and the syndrome of inappropriate anti-diuretic hormone (SIADH). Patients requiring urgent treatment to raise serum sodium to prevent or to treat serious neurological deficits should not be treated with SAMSCA. Additionally, it has not been established that raising serum sodium with SAMSCA provides a symptomatic benefit to patients. SAMSCA, an oral vasopressin V2-receptor antagonist, will be commercialized in the United States by Otsuka America Pharmaceutical, Inc. (OAPI).
generic viagra online
Drug Rescues Memory Lost To Alzheimer's Disease
A drug similar to one used in clinical trials for treatment of rheumatoid arthritis and psoriasis has been found to rescue memory in mice exhibiting Alzheimer"s symptoms.
News of the day
Osiris Therapeutics Reports Interim Data For COPD Stem Cell Study
Therapeutics, Inc. (NASDAQ:OSIR) announced six-month interim data from a Phase II clinical trial evaluating Prochymal, the Company"s proprietary formulation of adult mesenchymal stem cells, for the treatment of chronic obstructive pulmonary disease (COPD). Sixty-two patients were enrolled and are being followed for two years in the placebo-controlled study. At the six-month time-point, the data revealed several important findings.
Mental Health

Healthcare Leader Speaks Out On Latest Hospital "Epidemic"

A global healthcare senior executive has called the latest infection threat to confront the NHS "a national epidemic". Whilst Government statements imply that hospital acquired infections are in decline Jim Taylor, a former Smith & Nephew President and now CEO of infection prevention specialist Saniguard International, says that Norovirus is now an increasing threat to our NHS wards. His company is launching PatientGuard this month - an anti-infection kit created specifically for the UK public, designed to help halt the spread of viruses (including Norovirus & H1N1) & bacteria (including MRSA). His concern is backed up by the latest Department of Health statistics released on the 8 June which reveal a 23% increase in laboratory reports of Norovirus outbreaks in NHS hospitals and an incredible 282 ward closures this year as a result of the outbreaks. In addition the British Medical Association (BMA) claimed this month that a high throughput of patients and an over-reliance on deep cleans and alcohol hand gels is undermining the Government"s efforts in the fight against healthcare acquired infections (HAIs). Taylor comments "whilst less life-threatening than MRSA, Norovirus can have serious implications for those in hospital who are already weakened by other conditions. Research shows that the areas most likely to harbour infections include bed linen, nightgowns and near-patient hand touch sites such as bedside tables. It is understandable that the public would wish to take matters into their own hands by adopting their own anti-infection measures in hospital". Patient Guard


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009